Allarity Therapeutics (ALLR) Institutional Ownership $1.54 +0.04 (+2.67%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.52 -0.02 (-0.97%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Allarity Therapeutics (NASDAQ:ALLR)CurrentInstitutional OwnershipPercentage11.53%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$173.71KNumber ofInstitutional Sellers(last 12 months)0 Get ALLR Insider Trade Alerts Want to know when executives and insiders are buying or selling Allarity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ALLR Institutional Buying and Selling by Quarter Allarity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Jane Street Group LLC26,365$27K0.0%N/A0.175% 8/12/2025 XTX Topco Ltd50,950$51K0.0%N/A0.338% 8/8/2025 Geode Capital Management LLC50,650$51K0.0%+49.3%0.336% 2/17/2025 Stonepine Capital Management LLC67,289$79K0.1%N/A1.518% 11/15/2023 Sabby Management LLC359,400$268K0.2%N/A13.165% 11/15/2023 Armistice Capital LLC261,000$195K0.0%N/A9.560% (Data available from 1/1/2016 forward) ALLR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALLR shares? During the previous two years, the following institutional investors and hedge funds held shares of Allarity Therapeutics shares: Sabby Management LLC ($268K), Armistice Capital LLC ($195K), Stonepine Capital Management LLC ($79K), XTX Topco Ltd ($51K), and Geode Capital Management LLC ($51K), Jane Street Group LLC ($27K).Learn more on Allarity Therapeutics' institutional investors. What percentage of Allarity Therapeutics' stock is owned by institutional investors? 11.53% of Allarity Therapeutics' stock is owned by institutional investors. Learn more on ALLR's institutional investor holdings. Which institutional investors have been buying Allarity Therapeutics' stock? The following institutional investors have purchased Allarity Therapeutics' stock in the last 24 months: Sabby Management LLC ($359.40K), Armistice Capital LLC ($261K), Stonepine Capital Management LLC ($67.29K), XTX Topco Ltd ($50.95K), Jane Street Group LLC ($26.37K), and Geode Capital Management LLC ($16.73K). How much institutional buying is happening at Allarity Therapeutics? Institutional investors have bought a total of 161,333 shares in the last 24 months. This purchase volume represents approximately $173.71K in transactions. Related Companies ImageneBio Major Shareholders Eliem Therapeutics Major Shareholders Verrica Pharmaceuticals Major Shareholders ABVC BioPharma Major Shareholders Precision BioSciences Major Shareholders PDS Biotechnology Major Shareholders ImmuCell Major Shareholders Annovis Bio Major Shareholders Actinium Pharmaceuticals Major Shareholders Karyopharm Therapeutics Major Shareholders This page (NASDAQ:ALLR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
